The current shortage of Acyclovir, CAS number 59277-98-3, is of great concern to the medical community. As a valued and integral treatment for encephalitis, the shortage of Acyclovir for compounding pharmacies has created an urgent need for both patients and practitioners. The August 27, 2013 issue of the Neurology journal cautioned healthcare professionals to be[…]
Shortage of Acyclovir Leads to Dire Situation for Patients with Encephalitis
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Drug Shortage, OTC and Compounding Product, Patent Expiration 2017 Sep 18, 2013
Tenofovir Offers Significant Risk Reduction for Contracting the HIV Virus
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, Patent Expiration 2018 Tags: HIV infection Jul 31, 2013
Breaking news in the pharmaceutical world made headlines on June 12, 2013, when the Centers for Disease Control and Prevention revealed a study touting the prophylactic benefit of Tenofovir. Coined pre-exposure prophylaxis or PrEP, this study advocating the use of Tenofovir as an interventional pre-treatment was published in the Lancet in mid- June of 2013.[…]
Etravirine Remains a Formidable Treatment for AIDS
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, FDA Approved 2012, Patent Expiration 2019 Tags: AIDSHIV virus Jul 01, 2013
As a successful nonnucleoside reverse transcriptase inhibitor, Etravirine, CAS number 269055-15-4 is also known as the brand name Intelence. With the patent for Intelence set to expire for Janssen on November 5, 2019, additional research and development offering generic formulations of this effectual treatment for AIDS is sure to proliferate. Last year Etravirine was approved[…]
Daclatasvir and Asunaprevir are a Promising Oral Treatment for Patients with the Hepatitis C Virus
Antiviral, Drug Research & Development API Tags: Hepatitis Cribavirin Apr 29, 2013
The Hepatitis C virus is daunting in nature, affecting 180 million people worldwide and a little over 4 million people in the United States. As the leading cause of chronic liver disease, which often leads to liver cancer, hepatitis C is currently difficult to treat with success. The typical treatment for patients with hepatitis C[…]
Atazanavir Sulfate Gets a Nod at the 6th International AIDS Society Conference
Anti-Retroviral / Anti-HIV, Antiviral, Drug Research & Development API, Patent Expiration 2017 Tags: antiretroviralHIVNorvirRitonavir Jan 20, 2013
Atazanavir Sulfate, CAS No: 229975-97-7 is also known as the antiretroviral medication Reyataz. With the patent for Reyataz expiring on June 20, 2017 research and development teams are currently working on the development of a generic version of this vital drug. Indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection, atazanavir[…]
Acyclovir Successfully Halts the Spread of Herpes
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Drug Research & Development API, Patent Expiration 2017, TEVA API Jan 17, 2013
Acyclovir, known as the brand name Xerese, is an efficacious medication used to treat herpes labialis. Known commonly as cold sores or fever blisters, this form of the herpes virus is successfully treated with Acyclovir as a combination cream, alongside hydrocortisone. Marketed by Coria Laboratories, the patent for Xerese expires on January 24, 2017. The[…]
Rilpivirine Proves to be a Worthy HIV Opponent
Anti-Retroviral / Anti-HIV, Antiviral, FDA Approved 2011 Tags: EUHIV infectionvitamin D Nov 28, 2012
Rilpivirine is a non-nucleoside reverse transcriptase inhibitor {NTRI} known as the brand name Edurant. Rilpivirine is used to treat HIV-1 infection, and it is often dispensed alongside other antiretroviral agents. As a 25 milligram tablet designed to be taken once daily with food, rilpivirine is effective at decreasing the amount of HIV infection in the[…]
Lamivudine Is Still a Formidable Treatment for HIV and HBV
Anti-Retroviral / Anti-HIV, Antiviral, Patent Expiration 2016 Tags: antiretroviral therapychronic hepatitis BHIV virus Nov 12, 2012
Lamivudine is also known as Epvir. Marketed by GlaxoSmithKline, the patent for Epvir is due to expire on May 18, 2016. Lamivudine is an antiviral medication that prevents human immunodeficiency virus (HIV) or hepatitis B (HBV) virus cells from multiplying in the body. This medication will treat HIV and HBV, but it is not a[…]
West Nile Virus Cases Show a 35% Increase in One Week
Anti-Retroviral / Anti-HIV, Antiviral, Bulk Active Ingredient, Cardiovascular Agent, Drug Research & Development API, TEVA API Tags: Australiaribavirin Sep 13, 2012
The CDC announced on Tuesday September 13, 2012 that the West Nile virus outbreak, which recently hit the U.S., is showing no signs of relenting, with an astounding 35% increase in cases from last week. With 2,636 cases involving people, including 118 deaths, all states except Alaska and Hawaii have reported at least one case[…]
Entecavir Versus a Staggering Number of Hepatitis B Cases Worldwide
Antiviral, Patent Expiration 2015 Tags: CDCchronic hepatitis B Aug 03, 2012
Entecavir, CAS# 209216-23-9 may also be known by it’s brand name Baraclude. With the patent for Bristol-Myers Squibb’s Baraclude expiring on February 21, 2015, entecavir is on track to becoming a profitable generic product. Used to treat patients with chronic hepatitis B, entecavir is considered an antiviral medication. With a staggering 2 billion people around[…]
